Antiviral Resistance Surveillance in Japan

To support public health, the National Institute of Infectious Diseases (NIID) and local Public Health Institutes conduct nationwide surveillance to detect antiviral-resistant influenza viruses.

This surveillance monitors resistance to neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), the cap-dependent endonuclease inhibitor baloxavir, and the M2 inhibitor amantadine.

Clinical specimens are collected from patients at sentinel sites and processed by Public Health Institutes. Approximately 10–15% of virus isolates are randomly selected and sent to NIID for detailed testing.

Antiviral Susceptibility Influenza (WHO Global Influenza Programme)

• Laboratory methodologies for testing the antiviral susceptibility of influenza viruses

Research Findings from Antiviral Resistance Surveillance in Japan

• Published Articles

Detection of Antiviral-Resistant Influenza Viruses in Japan

• Antiviral resistance surveillance in Japan (as of May 9, 2025)
• Antiviral resistance surveillance in Japan (as of January 27, 2025)
• Antiviral resistance surveillance in Japan (as of January 24, 2025)
• Antiviral resistance surveillance in Japan (as of December 25, 2024)
• Antiviral resistance surveillance in Japan (as of November 13, 2024)
• Antiviral resistance surveillance in Japan (as of November 11, 2024)
• Antiviral resistance surveillance in Japan (as of September 13, 2024)
• Antiviral resistance surveillance in Japan (as of May 23, 2024)
• Antiviral resistance surveillance in Japan (as of February 20, 2024)
• Antiviral resistance surveillance in Japan (as of December 19, 2023)
• Antiviral resistance surveillance in Japan (as of November 8, 2023)
• Antiviral resistance surveillance in Japan (as of October 12, 2023)
• Antiviral resistance surveillance in Japan (as of August 21, 2023)
• Antiviral resistance surveillance in Japan (as of April 7, 2023)